You just read:

FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)

News provided by

Eisai Inc.

Feb 25, 2019, 08:01 ET